(Q37251132)

19 August 2017

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial (English)

1 reference

19 August 2017

0 references

0 references

11

Johnny Ludvigsson

1 reference

19 August 2017

Robert J Ferry

2

0 references

Kevan C Herold

10

object named as

Kevan C Herold

1 reference

19 August 2017

William Hagopian

1

1 reference

19 August 2017

Nicole Sherry

3

1 reference

19 August 2017

David Carlin

4

1 reference

19 August 2017

Ezio Bonvini

5

1 reference

19 August 2017

Syd Johnson

6

1 reference

19 August 2017

Kathryn E Stein

7

1 reference

19 August 2017

Scott Koenig

8

1 reference

19 August 2017

Anastasia G Daifotis

9

1 reference

19 August 2017

Protégé Trial Investigators

12

1 reference

19 August 2017

language of work or name

English

0 references

publication date

25 June 2013

1 reference

19 August 2017

1 reference

19 August 2017

62

1 reference

19 August 2017

11

1 reference

19 August 2017

3901-3908

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

19 August 2017

start time

30 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Immune therapy and β-cell death in type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

The T1D Exchange clinic registry

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Standards of medical care in diabetes--2011.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

GAD treatment and insulin secretion in recent-onset type 1 diabetes

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Residual Beta-cell Function and Its Metabolic Consequences

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Insulin secretion in type 1 diabetes

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3806608

CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice

3 December 2018

1 reference

12 December 2020

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Diagnosis and classification of diabetes mellitus

1 reference

12 December 2020

Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes

1 reference

12 December 2020

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

1 reference

12 December 2020

IAPP boosts islet macrophage IL-1 in type 2 diabetes

1 reference

12 December 2020

Otelixizumab in the treatment of type 1 diabetes mellitus

1 reference

12 December 2020

Identifiers

DOI

10.2337/DB13-0236

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

23801579

1 reference